Your browser doesn't support javascript.
loading
Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate.
Iida, Kenji; Abdelhamid Ahmed, Amr H; Nagatsuma, Akiko Kawano; Shibutani, Tomoko; Yasuda, Satoru; Kitamura, Michiko; Hattori, Chiharu; Abe, Manabu; Hasegawa, Jun; Iguchi, Takuma; Karibe, Tsuyoshi; Nakada, Takashi; Inaki, Koichiro; Kamei, Reiko; Abe, Yuki; Nomura, Taisei; Andersen, Jessica L; Santagata, Sandro; Hemming, Matthew L; George, Suzanne; Doi, Toshihiko; Ochiai, Atsushi; Demetri, George D; Agatsuma, Toshinori.
Afiliación
  • Iida K; Daiichi Sankyo, Co., Ltd., Tokyo, Japan. iida.kenji.ve@daiichisankyo.co.jp.
  • Abdelhamid Ahmed AH; Sarcoma and Bone Oncology Division, Medical Oncology Department, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Nagatsuma AK; Ludwig Center at Harvard, Boston, Massachusetts.
  • Shibutani T; Harvard Medical School, Boston, Massachusetts.
  • Yasuda S; Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa, Japan.
  • Kitamura M; Daiichi Sankyo, Co., Ltd., Tokyo, Japan.
  • Hattori C; Daiichi Sankyo, Co., Ltd., Tokyo, Japan.
  • Abe M; Daiichi Sankyo, Co., Ltd., Tokyo, Japan.
  • Hasegawa J; Daiichi Sankyo, Co., Ltd., Tokyo, Japan.
  • Iguchi T; Daiichi Sankyo, Co., Ltd., Tokyo, Japan.
  • Karibe T; Daiichi Sankyo, Co., Ltd., Tokyo, Japan.
  • Nakada T; Daiichi Sankyo, Co., Ltd., Tokyo, Japan.
  • Inaki K; Daiichi Sankyo, Co., Ltd., Tokyo, Japan.
  • Kamei R; Daiichi Sankyo, Co., Ltd., Tokyo, Japan.
  • Abe Y; Daiichi Sankyo RD Novare, Co. Ltd., Tokyo, Japan.
  • Nomura T; Daiichi Sankyo, Co., Ltd., Tokyo, Japan.
  • Andersen JL; Daiichi Sankyo, Co., Ltd., Tokyo, Japan.
  • Santagata S; National Institutes of Biomedical Innovations, Health and Nutrition, Osaka, Japan.
  • Hemming ML; Sarcoma and Bone Oncology Division, Medical Oncology Department, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • George S; Ludwig Center at Harvard, Boston, Massachusetts.
  • Doi T; Harvard Medical School, Boston, Massachusetts.
  • Ochiai A; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Demetri GD; Sarcoma and Bone Oncology Division, Medical Oncology Department, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Agatsuma T; Harvard Medical School, Boston, Massachusetts.
Cancer Discov ; 11(6): 1508-1523, 2021 06.
Article en En | MEDLINE | ID: mdl-33579785
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inmunoconjugados / Resistencia a Antineoplásicos / Tumores del Estroma Gastrointestinal / Receptores CCR / Neoplasias Gastrointestinales / Antineoplásicos Tipo de estudio: Clinical_trials / Diagnostic_studies País/Región como asunto: America do norte / Asia Idioma: En Revista: Cancer Discov Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Inmunoconjugados / Resistencia a Antineoplásicos / Tumores del Estroma Gastrointestinal / Receptores CCR / Neoplasias Gastrointestinales / Antineoplásicos Tipo de estudio: Clinical_trials / Diagnostic_studies País/Región como asunto: America do norte / Asia Idioma: En Revista: Cancer Discov Año: 2021 Tipo del documento: Article